MetaVia Inc. Share Price
MTVAMetaVia Inc. Stock Performance
Open $1.47 | Prev. Close $1.50 | Circuit Range N/A |
Day Range $1.43 - $1.47 | Year Range $0.56 - $12.68 | Volume 300 |
Average Traded $1.45 |
MetaVia Inc. Share Price Chart
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MetaVia Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Apr-26 | $1.47 | $1.46 | +0.00% |
30-Apr-26 | $1.47 | $1.46 | -3.00% |
29-Apr-26 | $1.59 | $1.50 | -6.83% |
28-Apr-26 | $1.59 | $1.61 | +3.54% |
27-Apr-26 | $1.55 | $1.55 | -1.27% |
24-Apr-26 | $1.55 | $1.57 | -2.17% |
22-Apr-26 | $1.56 | $1.61 | +1.90% |